Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21274401 | 0.84 | GABRA5 (0.39) | GABRA5HCRTR2KDM4EDGAT1HSD11B1 | |
| SCHEMBL20772625 | 0.83 | KDM1A (0.36) | ACACBGABRA5HCRTR2KDM4EDGAT1 | |
| SCHEMBL20772815 | 0.77 | KDM1A (0.40) | ACACBGABRA5HCRTR2DGAT1KDM1A | |
| SCHEMBL15918802 | 0.76 | ACACB (0.38) | ACACBKDM4EMBOAT4ALDH1A1SMN1; SMN2 | |
| SCHEMBL9931651 | 0.76 | ACACB (0.43) | ACACBKDM4E | |
| SCHEMBL1390734 | 0.76 | KDM1A (0.47) | ACACBGABRA5HCRTR2KDM4EDGAT1 | |
| SCHEMBL15968599 | 0.76 | MAPT (0.55) | ACACBGABRA5 | |
| SCHEMBL16213737 | 0.75 | ACACB (0.38) | ACACBMBOAT4KDM1AEP300 | |
| SCHEMBL15065435 | 0.74 | HTR7 (0.46) | ACACBMBOAT4KDM1A | |
| SCHEMBL15918805 | 0.74 | ACACB (0.39) | ACACBMBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752499-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2024-03-27 | — | — | EP | disclosed |
| CN-111770918-B | Inhibitors of TRPC6 | 勃林格殷格翰国际公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11485740-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| US-20200399282-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| US-20200399282-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | US | disclosed |
| EP-3752499-A1 | INHIBITORS OF TRPC6 | Boehringer Ingelheim International GmbH (DE) | 2020-12-23 | — | — | EP | disclosed |
| CN-111770918-A | Inhibitors of TRPC6 | 勃林格殷格翰国际公司 | 2020-10-13 | — | — | CN | disclosed |
| WO-2019158572-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019158572-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| EP-2948442-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-8877741-B2 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8877741-B2 | Pyrrolidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| WO-2014114578-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399282-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC4 | ACACB 2094/4885GABRA5 3448/4885HCRTR2 805/4885 |
| US-11485740-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC4 | ACACB 2094/4885GABRA5 3448/4885HCRTR2 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.